Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3909 in Advanced Breast Cancer
NCT05775575Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TQB3909 in breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity, Maximum Tolerated Dose and 1 more. Status: unknown.
02
Drugs
TQB3909
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05775575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775575.